Epigenetic Modifications: A Therapeutic Approach in Alzheimer's Disease

Alzheimer’s disease is a progressive neurodegenerative disease that has affected millions of people worldwide, marked by memory loss and cognitive deficits. Currently, treatments only attempt to alleviate symptoms rather than reversing neuronal damage or cognitive deficits. However, epigenetic therapies correlated with their subsequent epigenetic modifications have been shown to show potential in pre-clinical trials, prompting researchers to focus more on this subject matter. By examining many credible sources, this paper aims to highlight potential epigenetic modifications in Alzheimer’s disease patients and shed light on their subsequent epigenetic therapy. Ultimately, many pre-clinical trials have reiterated the potential these therapies have for reversing Alzheimer’s disease pathology and progression. The three primary epigenetic therapies highlighted include DNA methylation inhibitors, histone deacetylase (HDAC) inhibitors, and non-coding RNA-based therapies. Altogether, with further advances in pre-clinical trials and a transition into human clinical trials, the potential of these therapies can be utilized as a novel approach to reversing the damage that occurs from epigenetic modifications in Alzheimer’s patients.